Loading...
Keywords:
immune checkpoint inhibitor; Nivolumab; late onset Immune-related adverse event; arthritis
Recommended Citation
1. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39(36): 4073-126. 2. Liu H, Li Y, Li J, et al. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol 2023; 14: 1199031. 3. Ghosh N, Tiongson MD, Stewart C, et al. Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series. J Clin Rheumatol 2021; 27(8): e317-e22. 4. Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood 2022; 139(25): 3594-604. 5. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16(9): 563-80. 6. Pozas J, Cheruvu S, Jaganathan PP, et al. Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study. Cancers (Basel) 2025; 17(15). 7. Owen CN, Bai X, Quah T, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 2021; 32(7): 917-25.
Institutional Review Board/Institutional Animal Care and Use Committee Approved or Exempt
Not Applicable
When Immunotherapy Hits the Joints: A Case of Late-Onset Polyarthritis Induced by Immune Checkpoint Blockade